Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
235 Results for "
Progesterone
" in MedChemExpress (MCE) Product Catalog:
Products (235)
235 Results for "Progesterone" in MCE Product Catalog:
Cat. No.: HY-P702292
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: PAEP; PP14 Protein (Placental Protein 14); Progestagen Associated Endometrial Protein; Zona-Binding Inhibitory Factor-1; Glycodelin; Alpha Uterine Protein; PP14; Placental Protein 14; PAEG; Glycodelin-A; GD; Glycodelin-S; Progesterone-Associated Endometri
Species:
Virus
Source:
E. coli Cell-free
Cat. No.: HY-P703871
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: PAEP; PP14 Protein (Placental Protein 14); Progestagen Associated Endometrial Protein; Zona-Binding Inhibitory Factor-1; Glycodelin; Alpha Uterine Protein; PP14; Placental Protein 14; PAEG; Glycodelin-A; GD; Glycodelin-S; Progesterone-Associated Endometri
Species:
Virus
Source:
HEK293
Cat. No.: HY-P704068
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: PAEP; PP14 Protein (Placental Protein 14); Progestagen Associated Endometrial Protein; Zona-Binding Inhibitory Factor-1; Glycodelin; Alpha Uterine Protein; PP14; Placental Protein 14; PAEG; Glycodelin-A; GD; Glycodelin-S; Progesterone-Associated Endometri
Species:
Virus
Source:
HEK293
Cat. No.: HY-B0084S4
Synonyms: STS 557-13C,15N,d4
Target:
Research Areas:
Quinestrol (Standard) is the analytical standard of Quinestrol (HY-B1012). This product is intended for research and analytical applications. Quinestrol (W-3566) is an orally effective synthetic estrogen compound that acts on CYP3A4, CYP1A2, and GnRH. Quinestrol interferes with GnRH release and disrupts the hypothalamic-pituitary-ovarian axis. Quinestrol downregulates the gene expression of follicle-stimulating hormone β and luteinizing hormone β, induces oxidative stress, damages reproductive organs, reduces sperm density and motility, increases sperm malformation rate, and alters the levels of sex hormones such as testosterone, luteinizing hormone, estradiol, and progesterone. Quinestrol can be used in studies related to reproductive function regulation .
Cat. No.: HY-W490804
CAS No.: 2971-36-0
Target:
Research Areas:
HPTE is the active in vivo metabolite of Methoxychlor (HY-B1873), and acts as an inhibitor of 3β‑HSD and 17β‑HSD3. HPTE binds to the substrate-binding pocket of 3β‑HSD in a non-competitive manner, but competitively occupies the coenzyme NAD +-binding site, thereby inhibiting the conversion of pregnenolone to progesterone. HPTE binds to the androstenedione-binding pocket (the substrate pocket) of 17β‑HSD3 in a non-competitive manner, and competitively occupies the coenzyme NADPH-binding site, thus blocking the conversion of androstenedione to testosterone. HPTE interferes with androgen biosynthesis in Leydig cells by inhibiting the activities of these two key steroidogenic enzymes. HPTE can be used in studies related to androgen biosynthesis .
Cat. No.: HY-P85433
Synonyms: ST13; AAG2; FAM10A1; HIP; SNC6; Hsc70-interacting protein; Hip; Aging-associated protein 2; Progesterone receptor-associated p48 protein; Protein FAM10A1; Putative tumor suppressor ST13; Renal carcinoma antigen NY-REN-33; Suppression of tum
Target:
Research Areas:
6α-Fluorotestosterone is a non-aromatizable aromatase inhibitor, with IC50 values of 115 nM and 580 nM against human and rat aromatase, respectively. 6α-Fluorotestosterone binds to the substrate site of human aromatase P450arom with a Ki of 150 nM, but is not aromatized into estrogen. In vivo, 6α-Fluorotestosterone maintains sexual behavior in castrated male rats (with an effect comparable to that of testosterone), induces defeminization of sexual development, and inhibits nuclear translocation of hypothalamic estrogen receptors; its pro-mating effect is blocked by the aromatase inhibitors ATD and Fadrozole (HY-14247A). Combined with Progesterone (HY-N0437), 6α-Fluorotestosterone induces lordosis behavior in ovariectomized female rats. 6α-Fluorotestosterone can be used in studies related to anovulatory infertility and sexual behavior regulation .
Cat. No.: HY-W738639
CAS No.: 379-68-0
Synonyms: 18-OH-DOC; 11-Deoxy-18-hydroxycorticosterone
Research Areas:
18-Hydroxy-11-deoxy corticosterone (18-OH-DOC) is a mineralocorticoid whose synthesis is regulated by adrenocorticotropic hormone (ACTH) and angiotensin II.
18-Hydroxy-11-deoxy corticosterone is an intermediate in the metabolism of progesterone and plays an important role in regulating blood pressure and water-salt balance. Continuous infusion of
18-Hydroxy-11-deoxy corticosterone can increase systolic blood pressure in rats, and plasma levels of
18-Hydroxy-11-deoxy corticosterone are significantly elevated in the db/db mouse model of type 2 diabetes, suggesting its potential involvement in metabolic dysregulation and diabetes-related regulation.
18-Hydroxy-11-deoxy corticosterone holds promise for research in areas such as hypertension, diabetes, and other related fields .
Cat. No.: HY-158101R
CAS No.: 2446928-30-7
Synonyms: CC-94676 (Standard)
Research Areas:
BMS-986365 (Standard) is the analytical standard of BMS-986365 (HY-158101). This product is intended for research and analytical applications. BMS-986365 (CC-94676) is an orally active and selective targeted androgen receptor (AR) PROTAC degrader (DC50 of 10-40 nM). BMS-986365 is capable of inducing cereblon (CRBN) E3 ligase-dependent ubiquitination and degradation of the androgen receptor (AR), as well as various AR mutants. BMS-986365 shows no degradation of the close AR family members estrogen receptor (ER), progesterone receptor (PR), and glucocorticoid receptor (GR). BMS-986365 shows significant in vivo potency, degrading AR, inhibiting AR signaling, and restricting tumor growth in animal models of advanced prostate cancer. BMS-986365 can be used for the study of metastatic castration-resistant prostate cancer (mCRPC) .
Cat. No.: HY-141764S
CAS No.: 1794780-53-2
Research Areas:
2,2-Bis(p-hydroxyphenyl)-1,1,1-trichloroethane-d8 is the deuterated-labeled HPTE (HY-W490804). HPTE is the active in vivo metabolite of Methoxychlor (HY-B1873), and acts as an inhibitor of 3β‑HSD and 17β‑HSD3. HPTE binds to the substrate-binding pocket of 3β‑HSD in a non-competitive manner, but competitively occupies the coenzyme NAD +-binding site, thereby inhibiting the conversion of pregnenolone to progesterone. HPTE binds to the androstenedione-binding pocket (the substrate pocket) of 17β‑HSD3 in a non-competitive manner, and competitively occupies the coenzyme NADPH-binding site, thus blocking the conversion of androstenedione to testosterone. HPTE interferes with androgen biosynthesis in Leydig cells by inhibiting the activities of these two key steroidogenic enzymes. HPTE can be used in studies related to androgen biosynthesis .
Cat. No.: HY-P80401
Synonyms: AIG6, FKBP51, FKBP5, Peptidyl-prolyl cis-trans isomerase FKBP5, PPIase FKBP5, 51 kDa FK506-binding protein, 54 kDa Progesterone receptor-associated immunophilin, Androgen-regulated protein 6, FF1 antigen, FK506-binding protein 5, FKBP54, HSP90-binding immunophilin, Rotamase, 51 kDa FKBP, FKBP-51, FKBP-5, p54
Cat. No.: HY-P87541
Synonyms: AIG6, FKBP51, FKBP5, Peptidyl-prolyl cis-trans isomerase FKBP5, PPIase FKBP5, 51 kDa FK506-binding protein, 54 kDa Progesterone receptor-associated immunophilin, Androgen-regulated protein 6, FF1 antigen, FK506-binding protein 5, FKBP54, HSP90-binding immunophilin, Rotamase, 51 kDa FKBP, FKBP-51, FKBP-5, p54
Cat. No.: HY-L074
3,404 compounds
Breast cancer is the most frequent cancer among women, impacting 2.1 million women each year, and also causes the greatest number of cancer-related deaths among women. Surgery is usually the first type of treatment for breast cancer, which is usually followed by chemotherapy or radiotherapy or, in some cases, hormone or targeted therapies, especially for metastatic breast cancer (MBC).
Breast cancer is a heterogeneous disease, which is categorized into 3 major subtypes based on the presence or absence of molecular markers for estrogen or progesterone receptors and human epidermal growth factor 2 (ERBB2; formerly HER2): hormone receptor positive/ERBB2 negative (70% of patients), ERBB2 positive (15%-20%), and triple-negative (tumors lacking all 3 standard molecular markers; 15%). Different intrinsic subtypes exhibit different tumor behavior with different prognoses, and may require specific targeted therapies to maximize treatment effectiveness. Otherwise, some signaling pathways also play important roles in the development of breast cancer, such as NF-κB Signaling Pathway, TGF-beta Signaling Pathway, PI3K/AKT/mTOR signaling pathway and Notch Signaling Pathway. These signaling pathways offer ideal targets for development of new targeted therapies for breast cancer.
MCE supplies a unique collection of 3,404 compounds with identified and potential anti-breast cancer activity. MCE Anti-Breast Cancer Compound Library is a useful tool for anti-breast cancer drugs screening.
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
